Newsletter Archive

Protein Design Digest - 2026-01-07 - Discovery of PPARγ Partial Agonists for Treatment of Type 2 Diabetes Based on an Integrated Virtual Screening Strategy that Combines Fragment Molecular Orbital Calculations, Machine Learning, Molecular Docking, Interaction Fingerprint Filtering, and Molecular Dynamics Simulations.

Daily Archive

Issue #15: SMARTDock: A Toolkit for the Automated Development of Target-Specific Scoring Functions Using Bioactivity Data.

Issue #1: Discovery of PPARγ Partial Agonists for Treatment of Type 2 Diabetes Based on an Integrated Virtual Screening Strategy that Combines Fragment Molecular Orbital Calculations, Machine Learning, Molecular Docking, Interaction Fingerprint Filtering, and Molecular Dynamics Simulations.

Issue #1: AlphaFold for Docking Screens.

Issue #14: Assessing the validity of leucine zipper constructs predicted by AlphaFold.

Issue #13: AlphaFold for Docking Screens.

Issue #1: AlphaFold for Docking Screens.

Weekly Digest: Dec 28 - Jan 04, 2026

Issue #13: AlphaFold for Docking Screens.

Issue #12: AlphaFold for Docking Screens.

Issue #12: Integrated cytotoxicity screening and in silico analysis of coumarin nucleoside conjugates as computationally modeled VEGFR-2 inhibitors: oncocyte cytotoxicity, molecular docking, and dynamics simulation studies.

Issue #11: Integrated cytotoxicity screening and in silico analysis of coumarin nucleoside conjugates as computationally modeled VEGFR-2 inhibitors: oncocyte cytotoxicity, molecular docking, and dynamics simulation studies.

Issue #1: Integrated cytotoxicity screening and in silico analysis of coumarin nucleoside conjugates as computationally modeled VEGFR-2 inhibitors: oncocyte cytotoxicity, molecular docking, and dynamics simulation studies.

Issue #1: Integrated cytotoxicity screening and in silico analysis of coumarin nucleoside conjugates as computationally modeled VEGFR-2 inhibitors: oncocyte cytotoxicity, molecular docking, and dynamics simulation studies.

Issue #10: Integrated cytotoxicity screening and in silico analysis of coumarin nucleoside conjugates as computationally modeled VEGFR-2 inhibitors: oncocyte cytotoxicity, molecular docking, and dynamics simulation studies.

Issue #1: Integrated cytotoxicity screening and in silico analysis of coumarin nucleoside conjugates as computationally modeled VEGFR-2 inhibitors: oncocyte cytotoxicity, molecular docking, and dynamics simulation studies.

Issue #9: Integrated cytotoxicity screening and in silico analysis of coumarin nucleoside conjugates as computationally modeled VEGFR-2 inhibitors: oncocyte cytotoxicity, molecular docking, and dynamics simulation studies.

Issue #1: Integrated cytotoxicity screening and in silico analysis of coumarin nucleoside conjugates as computationally modeled VEGFR-2 inhibitors: oncocyte cytotoxicity, molecular docking, and dynamics simulation studies.

Issue #8: Integrated cytotoxicity screening and in silico analysis of coumarin nucleoside conjugates as computationally modeled VEGFR-2 inhibitors: oncocyte cytotoxicity, molecular docking, and dynamics simulation studies.

Issue #1: Integrated cytotoxicity screening and in silico analysis of coumarin nucleoside conjugates as computationally modeled VEGFR-2 inhibitors: oncocyte cytotoxicity, molecular docking, and dynamics simulation studies.

Issue #7: Integrated cytotoxicity screening and in silico analysis of coumarin nucleoside conjugates as computationally modeled VEGFR-2 inhibitors: oncocyte cytotoxicity, molecular docking, and dynamics simulation studies.

Issue #1: Integrated cytotoxicity screening and in silico analysis of coumarin nucleoside conjugates as computationally modeled VEGFR-2 inhibitors: oncocyte cytotoxicity, molecular docking, and dynamics simulation studies.

Weekly Digest: Dec 21 - Dec 28, 2025

Issue #7: Integrated cytotoxicity screening and in silico analysis of coumarin nucleoside conjugates as computationally modeled VEGFR-2 inhibitors: oncocyte cytotoxicity, molecular docking, and dynamics simulation studies.

Issue #5: Integrated cytotoxicity screening and in silico analysis of coumarin nucleoside conjugates as computationally modeled VEGFR-2 inhibitors: oncocyte cytotoxicity, molecular docking, and dynamics simulation studies.

Issue #1: Integrated cytotoxicity screening and in silico analysis of coumarin nucleoside conjugates as computationally modeled VEGFR-2 inhibitors: oncocyte cytotoxicity, molecular docking, and dynamics simulation studies.

Issue #1: Integrated cytotoxicity screening and in silico analysis of coumarin nucleoside conjugates as computationally modeled VEGFR-2 inhibitors: oncocyte cytotoxicity, molecular docking, and dynamics simulation studies.

Issue #1: Integrated cytotoxicity screening and in silico analysis of coumarin nucleoside conjugates as computationally modeled VEGFR-2 inhibitors: oncocyte cytotoxicity, molecular docking, and dynamics simulation studies.

Issue #4: Cytotoxicity, apoptosis, molecular docking, and molecular dynamics study of novel compounds of Sulfamide derivatives coupled with DHP scaffolds as potent inhibitors of the MCF-7, A549, SKOV-3, and EA. yh926 carcinoma cells.

Issue #1: Cytotoxicity, apoptosis, molecular docking, and molecular dynamics study of novel compounds of Sulfamide derivatives coupled with DHP scaffolds as potent inhibitors of the MCF-7, A549, SKOV-3, and EA. yh926 carcinoma cells.

Issue #3: A Comparative Study of Deep Learning and Classical Modeling Approaches for Protein-Ligand Binding Pose and Affinity Prediction in Coronavirus Main Proteases.

Issue #1: Cytotoxicity, apoptosis, molecular docking, and molecular dynamics study of novel compounds of Sulfamide derivatives coupled with DHP scaffolds as potent inhibitors of the MCF-7, A549, SKOV-3, and EA. yh926 carcinoma cells.

Issue #3: Cytotoxicity, apoptosis, molecular docking, and molecular dynamics study of novel compounds of Sulfamide derivatives coupled with DHP scaffolds as potent inhibitors of the MCF-7, A549, SKOV-3, and EA. yh926 carcinoma cells.

Issue #2: Cytotoxicity, apoptosis, molecular docking, and molecular dynamics study of novel compounds of Sulfamide derivatives coupled with DHP scaffolds as potent inhibitors of the MCF-7, A549, SKOV-3, and EA. yh926 carcinoma cells.

Weekly Digest: Dec 14 - Dec 21, 2025

Issue #2: Meeko: Molecule Parametrization and Software Interoperability for Docking and Beyond.